Medwave Inc., of Danvers, Mass., has received clearance to market Fusion, the first completely sensor-based monitor to evaluate BP and vital signs. Studies have demonstrated that the accuracy of Medwave’s core sensor-based BP technology is comparable to that of an invasive arterial catheter. The new monitor, which takes readings at the wrist, expands the technology by incorporating sensor-based pulse oximetry by Nellcor and thermometry by Kendall (both operating companies of Tyco Healthcare Group, LP, of Mansfield, Mass.). “Health providers now have a device to continually monitor vital signs without invasive techniques. That’s something we never could have imagined 30 years ago,” said Medwave chief executive officer Tim O’Malley.
Publish Date
